Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

A federal district court in Texas on Thursday denied a request for a preliminary injunction from the Outsourcing Facilities ...

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

The decision came in response to a February lawsuit from a compounding industry group against the FDA's decision that there ...

Weight loss injections boost the glucagon-like peptide-1 (GLP-1) hormone, which is a naturally produced hormone in the ...

Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...

The California Legislative Analyst’s Office reports the state’s drug spending has doubled since 2018, with a quarter of the ...

Gavin Newsom’s administration has reported that half of the doubling in Medi-Cal costs over the past six years has been from ...